A Phase II Study of Midostaurin and 5-Azacitidine for Untreated Elderly and Unfit Patients With FLT3 Wild-type Acute Myelogenous Leukemia-Reference-Cited by-同舟云学术

A Phase II Study of Midostaurin and 5-Azacitidine for Untreated Elderly and Unfit Patients With FLT3 Wild-type Acute Myelogenous Leukemia

Published:2020-04 Issue:4 Volume:20 Page:226-233.e1
ISSN:2152-2650
Container-title:Clinical Lymphoma Myeloma and Leukemia
language:en
Short-container-title:Clinical Lymphoma Myeloma and Leukemia

Author:

Tomlinson Benjamin K.,Gallogly Molly M.,Kane Donna M.,Metheny Leland,Lazarus Hillard M.,William Basem M.,Craig Michael D.,Levis Mark J.,Cooper Brenda W.

Funder

Novartis

Astellas

FijiFilm

Case Comprehensive Cancer Center Core

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference32 articles.

1. Cancer statistics, 2018;Siegel;CA Cancer J Clin,2018

2. Age and acute myeloid leukemia;Appelbaum;Blood,2006

3. Acute myeloid leukemia and myelodysplastic syndromes in older patients;Estey;J Clin Oncol,2007

4. Big data analysis of treatment patterns and outcomes among elderly acute myeloid leukemia patients in the United States;Medeiros;Ann Hematol,2015

5. Epigenetic treatment of hematopoietic malignancies: in vivo targets of demethylating agents;Claus;Semin Oncol,2005

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The potential of triplet combination therapies for patients with FLT3-ITD -mutated acute myeloid leukemia;Expert Review of Hematology;2024-05-20

2. Managing infectious challenges in the age of molecular‐targeted therapies for adult hematological malignancies;Transplant Infectious Disease;2024-05-02

3. Theoretical models of staurosporine and analogs uncover detailed structural information in biological solution;Journal of Molecular Graphics and Modelling;2024-01

4. Flow cytometry of DNMT1 as a biomarker of hypomethylating therapies;Cytometry Part B: Clinical Cytometry;2024-01

5. Venetoclax in adult acute myeloid leukemia;Biomedicine & Pharmacotherapy;2023-12